C. Sadler, C. Sadler, K.W. Gow, E.A. Beierle, J.J. Doski, M. Langer, J.G. Nuchtern, S.A. Vasudevan, M. Goldfarb, Parathyroid carcinoma in more than 1,000 patients: a population-level analysis. Surgery 156, 1622–1629 (2014)
D. Betea, I. Potorac, A. Beckers, Parathyroid carcinoma: challenges in diagnosis and treatment. Ann. Endocrinol. 76, 169–177 (2015)
A.S. Salcuni, F. Cetani, V. Guarnieri, V. Nicastro, E. Romagnoli, D. de Martino, A. Scillitani, D.E.C. Cole, Parathyroid carcinoma. Best Pract. Res. Clin. Endocrinol. Metab. 32, 877–889 (2018)
K. Brewer., J. Costa-Guda, A. Arnold, Molecular genetic insights into sporadic primary hyperparathyroidism. Endocr. Relat. Cancer 26, R53–R72 (2019)
E. Cavalier, A.F. Daly, D. Betea, P.N. Pruteanu-Apetrii, P. Delanaye, P. Stubbs, A.R. Bradwell, J.P. Chapelle, A. Beckers, The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker of parathyroid carcinoma. J. Clin. Endocrinol. Metab. 95, 3745–3749 (2010)
A. Harari, A. Waring, G. Fernandez-Ranvier, J. Hwang, I. Suh, E. Mitmaker, W. Shen, J. Gosnell, Q.Y. Duh, O. Clark, Parathyroid carcinoma: a 43-year outcome and survival analysis. J. Clin. Endocrinol. Metab. 96, 3679–3686 (2011)
E.A. Asare, C. Sturgeon, D.J. Winchester, L. Liu, B. Palis, N.D. Perrier, D.B. Evans, D.P. Winchester, T.S. Wang, Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann. Surg. Oncol. 22, 3990–3995 (2015)
Y. Takeuchi, S. Takahashi, D. Miura, M. Katagiri, N. Nakashima, H. Ohishi, R. Shimazaki, Y. Tominaga, Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism. J. Bone Min. Metab. 35, 616–622 (2017)
A.R. Bradwell, T.C. Harvey, Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 353, 370–373 (2019)
D. Betea, A.R. Bradwell, T.C. Harvey, G.P. Mead, H. Schmidt-Gayk, B. Ghaye, A.F. Daly, A. Beckers, Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J. Clin. Endocrinol. Metab. 89, 3413–3420 (2014)
I. Horie, T. Ando, N. Inokuchi, Y. Mihara, S. Miura, M. Imaizumi, T. Usa, N. Kinoshita, I. Sekine, S. Kamihara, K. Eguchi, First Japanese patient treated with parathyroid hormone peptide immunization for refractory hypercalcemia caused by metastatic parathyroid carcinoma. Endocr. J. 57, 287–292 (2010)
V.M. Howell, C.J. Haven, K. Kahnoski, S.K. Khoo, D. Petillo, J. Chen, G.J. Fleuren, B.G. Robinson, L.W. Delbridge, J. Philips, A.E. Nelson, U. Krause, K. Hammje, H. Dralle, C. Hoang-Vu, O. Gimm, D.J. Marsh, H. Morreau, B.T. The, HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J. Med Genet. 40, 657–663 (2003)
M.S. Sarquis, L.G. Silveira, F.J. Pimenta, E.P. Dias, B.T. Teh, E. Friedman, R.S. Gomez, G.C. Tavares, C. Eng, L. De Marco, Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery 43, 630–640 (2008)
L. Rozhinskaya, E. Pigarova, E. Sabanova, E. Mamedova, I. Voronkova, J. Krupinova, L. Dzeranova, A. Tiulpakov, V. Gorbunova, N. Orel, A. Zalian, G. Melnichenko, I. Dedov, Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases. Endocrinol. Diabetes Metab. Case Rep. 6, 0113 (2017)
C.N. Clarke, P. Katsonis, T.K. Hsu, A.M. Koire, A. Silva-Figueroa, I. Christakis, M.D. Williams, M. Kutahyalioglu, L. Kwatampora, Y. Xi, J.E. Lee, E.S. Koptez, N.L. Busaidy, N.D. Perrier, O. Lichtarge, Comprehensive genomic characterization of parathyroid cancer identifies novel candidate driver mutations and core pathways. J. Endocr. Soc. 3, 544–559 (2018)
P. Piranavan, Y. Li, E. Brown, E.H. Kemp, N. Trivedi, Immune checkpoint inhibitor-induced hypoparathyroidism associated with Calcium-Sensing Receptor-Activating autoantibodies. J. Clin. Endocrinol. Metab. 104, 550–556 (2019)
